Medicus Pharma Ltd (MDCX)
NASDAQ (CM) NASDAQ (CM) Primary 
Medicus Pharma CEO discusses promising Phase 2 SkinJect results - ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week highlighted encouraging data from its Phase 2 clinical trial evaluating SkinJect, a non-invasive treatment...
Medicus says Phase 2 data supports further development of SkinJect therapy for skin cancer
Medicus Pharma (NASDAQ:MDCX) said on Monday that new analysis of data from a mid-stage clinical trial of its SkinJect microneedle therapy showed encouraging results in treating basal cell carcinoma, the most common form of skin cancer. The Medicus Pharma Ltd said the Phase 2 SKNJCT-003 study evaluating its SkinJect microneedle delivery system achieved 73% clinical clearance and 40% histological clearance in patients treated with a 200-microgram dose by Day 57, the strongest treatment response seen in the trial.
Medicus Pharma CEO discusses Phase 2 skin cancer results - ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Dr. Raza Bokhari talked with Proactive about the company's newly reported topline Phase 2 results for its microneedle array patch technology targeting basal cell carcinoma, a common form of non-melanoma skin cancer.
Medicus Pharma reports positive Phase 2 results for microneedle treatment for basal cell carcinoma
Medicus Pharma (NASDAQ:MDCX) said on Thursday that its experimental microneedle-based therapy showed encouraging efficacy in a mid-stage clinical trial for treating Basal Cell Carcinoma, with the highest-dose group achieving 73% clinical clearance of lesions. The Phase 2 randomized, double-blind, placebo-controlled study enrolled 90 patients with nodular basal cell carcinoma and evaluated two doses of the company's doxorubicin microneedle array (D-MNA), a non-invasive treatment designed to deliver chemotherapy through the skin.
Medicus Pharma's Teverelix Phase 2b trial cleared by FDA - ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the FDA's clearance to begin a Phase 2b dose optimization study for Teverelix, the company's next-generation GnRH antagonist targeting advanced prostate cancer. Proactive: All right.
Medicus Pharma receives FDA clearance to proceed with Phase 2b prostate cacner study
Medicus Pharma (NASDAQ:MDCX) announced that it has received “study may proceed” clearance from the US Food and Drug Administration (FDA) to initiate a Phase 2b dose-optimization study of Teverelix, its investigational long-acting gonadotropin-releasing hormone (GnRH) antagonist, in men with advanced prostate cancer and elevated cardiovascular risk. The open-label Phase 2b trial is expected to enroll 40 patients who are candidates for androgen deprivation therapy.
Medicus Pharma marks Nasdaq milestone as it advances Phase 2 clinical programs
Medicus Pharma (NASDAQ:MDCX) has marked the one-year anniversary of its Nasdaq listing on Thursday by ringing the Opening Bell at the Nasdaq MarketSite in New York's Times Square. CEO Dr Raza Bokhari said the company was honored with the opportunity, describing the milestone as a reflection of Medicus' progress since going public and its continued focus on disciplined execution across a streamlined and strategically selected clinical portfolio.
Medicus Pharma lowers royalty burden on prostate cancer drug Teverelix
Medicus Pharma (NASDAQ:MDCX) said on Thursday its subsidiary Antev Ltd has amended a licensing agreement with UK-based medical research organization LifeArc, reducing future royalties tied to the experimental drug Teverelix, a move the company said improves the asset's long-term commercial profile. Under the revised agreement, royalties payable on worldwide net sales of Teverelix have been cut to 2% from about 4%, with the royalty term clarified on a country-by-country basis, Medicus said.
Medicus Pharma advances Teverelix program, set to present Phase 1 data at AACE Annual Meeting
Medicus Pharma (NASDAQ:MDCX) announced that it will present new Phase 1 clinical data on its long-acting gonadotropin-releasing hormone (GnRH) antagonist Teverelix at the American Association of Clinical Endocrinology (AACE) Annual Meeting in April 2026. The company said its abstract, titled “Evaluation of Teverelix, a Long-Acting GnRH Antagonist: Pharmacokinetics, Pharmacodynamics, Bone Turnover and Safety in Two Phase 1 Studies in Healthy Female Volunteers,” has been accepted for e-Poster presentation at the meeting, which will be held April 22 to 24 in Las Vegas.
Medicus Pharma signs non-binding AI collaboration to support clinical trials
Medicus Pharma (NASDAQ:MDCX) said on Monday it has entered into a letter of intent with Reliant AI Inc to collaborate on the development of an artificial-intelligence-powered data analytics platform aimed at improving the execution of its clinical trials. The Nasdaq-listed biotechnology company said the proposed platform would integrate Reliant's generative AI technology with Medicus' clinical, operational and proprietary datasets to support data-driven decision-making across its development pipeline.
Medicus Pharma completes SkinJect trial enrolment – ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Dr Raza Bokhari talked with Proactive about the company completing patient enrollment in its SkinJect clinical trial. The company has now enrolled 90 patients across nine sites in the United States as part of its clinical development program for Skinject, a novel, noninvasive treatment for non-melanoma skin diseases, specifically basal cell carcinoma.
Medicus Pharma completes enrollment for Phase 2 basal cell carcinoma study
Medicus Pharma (NASDAQ:MDCX) announced that it has completed enrollment of 90 patients in its Phase 2 clinical study evaluating a non-invasive treatment for basal cell carcinoma (BCC) of the skin. The study, known as SKNJCT-003, is assessing the safety and efficacy of the company's doxorubicin microneedle array (D-MNA) in patients with nodular BCC.
